Zydus Cadila gets USFDA approval for Potassium Chloride Extended-Release Tablets

Source

Team Infinities:

Cadila Healthcare Limited NSE symbol: CADILAHC, BSE script code: 53232,  a global pharmaceutical company, has received final approval from the USFDA (United States Food and Drug Administration) to market Potassium Chloride Extended-Release Tablets (in the strengths of 10 mEq (milliequivalents per litre) (750 mg) and 20 mEq (1500 mg).

The tablets are mineral supplements used to treat or prevent low blood-potassium levels. The medicine will be manufactured at company’s manufacturing facility at the SEZ (Special Economic Zone) in Ahmedabad. The company now has 301 approvals and has filed over 390 ANDAs (Abbreviated New Drug Applications) since the commencement of the filing process in financial year 2003-04.

Add new comment

Comment Editor

  • No HTML tags allowed.